Not available
Quote | OptiNose Inc. (NASDAQ:OPTN)
Last: | $1.045 |
---|---|
Change Percent: | -0.95% |
Open: | $1.06 |
Close: | $1.045 |
High: | $1.06 |
Low: | $1.04 |
Volume: | 289,122 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | OptiNose Inc. (NASDAQ:OPTN)
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
2024-05-17 20:55:21 ET OptiNose, Inc. (OPTN) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street C...
Message Board Posts | OptiNose Inc. (NASDAQ:OPTN)
Subject | By | Source | When |
---|---|---|---|
$OPTN OPTINOSE INC | MiamiGent | investorshub | 08/04/2020 2:13:25 PM |
$OPTN 5.87 up tick | MiamiGent | investorshub | 08/04/2020 1:56:25 PM |
Press Release: Optinose Reports Second Quarter 2020 Financial | MiamiGent | investorshub | 08/04/2020 11:42:28 AM |
$OPTN 5.72 +12% | MiamiGent | investorshub | 08/03/2020 7:10:50 PM |
OPTN $AUG 04 | MiamiGent | investorshub | 08/03/2020 5:01:33 PM |
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...